Detection of Lymph Node Involvement by Cytokeratin Immunohistochemistry is an Independent Prognostic Factor After Curative Resection of Esophageal Cancer

Journal of Gastrointestinal Surgery

Volumn 15, Issue 1, 2011, Pages 29-37

  Marjanovic, Goran ^a   Schricker, Markus ^a   Walch, Axel ^a   Hausen, Axel zur ^a   Hopt, Ulrich T ^a   Imdahl, Andreas ^b   Makowiec, Frank ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Klinikum Heidenheim   (Germany)

Author keywords

Esophageal cancer; Lymph node metastasis; Micrometastasis; Prognosis; Survival

Indexed keywords

EID: 78751580317     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1359-8     Document Type: Article

References (42)

1. Gee DW and Rattner DW. Management of gastroesophageal tumors. Oncologist 2007; 12(2): 175-85.
2. Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, Knoefel WT, and Izbicki JR. Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol 2001; 19(7): 1970-5.
3. Xiao ZF, Yang ZY, Miao YJ, Wang LH, Yin WB, Gu XZ, Zhang DC, Sun KL, Chen GY, and He J. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 549 cases. Int J Radiat Oncol Biol Phys 2005; 62(1): 82-90.
4. Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, and Siewert JR. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005; 242(4): 566-73; discussion 573-5.
5. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, van Raemdonck D, and Ectors N. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240(6): 962-72; discussion 972-4.
6. Chen G, Wang Z, Liu XY, and Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg 2007; 31(5): 1107-14.
7. Law SY, Fok M, and Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996; 83(1): 107-11.
8. Mariette C, Taillier G, van Seuningen I, and Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004; 78(4): 1177-83.
9. Keene SA and Demeure MJ. The clinical significance of micrometastases and molecular metastases. Surgery 2001; 129(1): 1-5.
10. Hermanek P, Hutter RV, Sobin LH, and Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86(12): 2668-73.
11. Tseng SC, Jarvinen MJ, Nelson WG, Huang JW, Woodcock-Mitchell J, and Sun TT. Correlation of specific keratins with different types of epithelial differentiation: monoclonal antibody studies. Cell 1982; 30(2): 361-72.
12. Glickman JN, Torres C, Wang HH, Turner JR, Shahsafaei A, Richards WG, Sugarbaker DJ, and Odze RD. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer 1999; 85(4): 769-78.
13. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, and Pantel K. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997; 337(17): 1188-94.
14. Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, and Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000; 127(1): 40-6.
15. Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, and Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998; 83(5): 858-66.
16. Sato F, Shimada Y, Li Z, Watanabe G, Maeda M, and Imamura M. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg 2001; 88(3): 426-32.
17. Tanabe T, Nishimaki T, Watanabe H, Ajioka Y, Akazawa K, Komukai S, and Hatakeyama K. Immunohistochemically detected micrometastasis in lymph nodes from superficial esophageal squamous cell carcinoma. J Surg Oncol 2003; 82(3): 153-9.
18. Waterman TA, Hagen JA, Peters JH, DeMeester SR, Taylor CR, and Demeester TR. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma. Ann Thorac Surg 2004; 78(4): 1161-9; discussion 1161-9.
19. O'Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, and Shanahan F. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 1999; 116(3): 543-8.
20. Doki Y, Ishikawa O, Mano M, Hiratsuka M, Sasaki Y, Kameyama M, Ohigashi H, Murata K, Yamada T, Miyashiro I, Yokoyama S, Ishiguro S, and Imaoka S. Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers. J Surg Res 2002; 107(1): 75-81.
21. Imdahl A, Schoffel U, Ruf G, and Hopf UT. [Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients]. Zentralbl Chir 2004; 129(5): 350-5.
22. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, and Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337(3): 161-7.
23. Naunheim KS, Petruska PJ, Roy TS, Schlueter JM, Kim H, and Baue AE. Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg 1995; 59(5): 1085-90; discussion 1090-1.
24. Hosch SB, Steffani KD, Scheunemann P, and Izbicki JR. Micrometastases from HBP malignancies and metastatic cancer. J Hepatobiliary Pancreat Surg 2002; 9(5): 583-91.
25. Kaifi JT, Reichelt U, Quaas A, Schurr PG, Wachowiak R, Yekebas EF, Strate T, Schneider C, Pantel K, Schachner M, Sauter G, and Izbicki JR. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007; 20(11): 1183-90.
26. Kanemitsu K, Hiraoka T, Tsuji T, Inoue K, and Takamori H. Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer. Pancreas 2003; 26(4): 315-21.
27. Izbicki JR, Passlick B, Hosch SB, Kubuschock B, Schneider C, Busch C, Knoefel WT, Thetter O, and Pantel K. Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg 1996; 112(3): 623-30.
28. Passlick B, Izbicki JR, Kubuschok B, Thetter O, and Pantel K. Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 1996; 61(1): 177-82; discussion 183.
29. Gillanders WE, Mikhitarian K, Hebert R, Mauldin PD, Palesch Y, Walters C, Urist MM, Mann GB, Doherty G, Herrmann VM, Hill AD, Eremin O, El-Sheemy M, Orr RK, Valle AA, Henderson MA, Dewitty RL, Sugg SL, Frykberg E, Yeh K, Bell RM, Metcalf JS, Elliott BM, Brothers T, Robison J, Mitas M, and Cole DJ. Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study. Ann Surg 2004; 239(6): 828-37; discussion 837-40.
30. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, Passlick B, Izbicki JR, and Riethmuller G. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3(3): 165-73.
31. Yekebas EF, Schurr PG, Kaifi JT, Link BC, Kutup A, Mann O, Wolfram L, and Izbicki JR. Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol 2006; 93(7): 541-9.
32. Jiao X, Eslami A, Ioffe O, Kwong KF, Henry M, Zeng Q, Refaely Y, Burrows W, Gamliel Z, and Krasna MJ. Immunohistochemistry analysis of micrometastasis in pretreatment lymph nodes from patients with esophageal cancer. Ann Thorac Surg 2003; 76(4): 996-9; discussion 999-1000.
33. Bonavina L, Soligo D, Quirici N, Bossolasco P, Cesana B, Lembertenghi Deliliers G, and Peracchia A. Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia. Surgery 2001; 129(1): 15-22.
34. Heeren PA, Kelder W, Blondeel I, van Westreenen HL, Hollema H, and Plukker JT. Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol 2005; 31(3): 270-6.
35. Vazquez-Sequeiros E, Wang L, Burgart L, Harmsen W, Zinsmeister A, Allen M, Jondal M, and Wiersema M. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology 2002; 122(7): 1815-21.
36. Matsumoto M, Natsugoe S, Nakashima S, Sakamoto F, Okumura H, Sakita H, Baba M, Takao S, and Aikou T. Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer Lett 2000; 153(1-2): 189-97.
37. Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, Yamasaki M, Makari Y, Matsuura N, Mano M, and Monden M. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 2007; 141(5): 570-80.
38. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, Falchi AM, Craxi A, and Camma C. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53(7): 925-30.
39. Urschel JD and Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185(6): 538-43.
40. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, and Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003; 10(7): 754-61.
41. Imdahl A, Schoffel U, and Ruf G. Impact of neoadjuvant therapy of perioperative morbidity in patients with esophageal cancer. Am J Surg 2004; 187(1): 64-8.
42. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, and Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23(19): 4330-7.